Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.

Biotechnology

Health Care

Health Diagnostics

Abdera Therapeutics

Lori Lyons-Williams

Philippe Bishop M.D.

Emma Cummins

Mike Abrams

Lana Janes

Alison Armour

Kelly Parker

Jennifer McNealey

Kawa Chiu

Leadership Team

Directors Team

Operations and Support Team

Science and Research Team

Finance Team

Founders and Senior Advisors

Teams at Abdera Therapeutics